TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has provided an update.
Botanix Pharmaceuticals Limited announced that its Executive Chairman, Vince Ippolito, will present at the HC Wainwright 27th Annual Global Investment Conference in New York. This event is significant as it attracts numerous institutional fund managers and showcases promising global growth companies, particularly in the healthcare and life sciences sectors. The presentation is expected to enhance Botanix’s visibility and potentially impact its market positioning by highlighting its innovative solutions in dermatology.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a dermatology company based in Philadelphia and Phoenix, specializing in innovative clinical dermatology solutions. The company has received FDA approval for its lead product, Sofdra, which is the first and only new chemical entity approved to treat primary axillary hyperhidrosis, offering a novel and effective treatment for this condition.
Average Trading Volume: 14,646,642
Technical Sentiment Signal: Sell
Current Market Cap: A$264.8M
See more insights into BOT stock on TipRanks’ Stock Analysis page.